Ally Bridge Group (Ny) LLC Intellia Therapeutics, Inc. Transaction History

Ally Bridge Group (Ny) LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $2.31 Million - $4.57 Million	-60,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$58.27 - $118.99 $291,350 - $594,950	-5,000 Reduced 7.69%	60,000 $4.36 Million
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $3.72 Million - $4.97 Million	-28,127 Reduced 30.2%	65,000 $8.72 Million
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $8.03 Million - $21.4 Million	-131,873 Reduced 58.61%	93,127 $15.1 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $4.24 Million - $14.3 Million	225,000 New	225,000 $12.2 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $916M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.